Latest news with #TakedaPharmaceutical
Nikkei Asia
8 hours ago
- Business
- Nikkei Asia
Takeda's downsized bond offering reveals new investor caution
TOKYO -- Takeda Pharmaceutical last week set the terms for the issuance of three tranches of straight bonds totaling 184 billion yen ($1.27 billion). But the Japanese drugmaker fell short of its 200 billion yen target, a sign that the market is now wary about large issuances. The bond market has settled down after a turbulent April, but it remains volatile compared with Japan's period of zero or negative interest rates. Some market participants note it can be difficult to absorb even highly rated bonds when there are successive large-volume issuances.
Nikkei Asia
22-04-2025
- Business
- Nikkei Asia
Japan drug companies offer rare haven amid Trump market jitters
TOKYO -- As nerves fray over tariff threats from U.S. President Donald Trump, large Japanese pharmaceutical companies have largely held their value even as other manufacturers like autos and semiconductors have endured a market sell-off. Take for example Takeda Pharmaceutical, a company that depends on overseas markets for 89% of its revenue, with the U.S. alone accounting for 51.5%. Its share price has mostly stayed above water year-to-date, even during the broader market's near 20% tumble this month, with investors saying that its blood plasma products are locally produced and unlikely to be affected by any tariffs.
Japan Times
30-01-2025
- Business
- Japan Times
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running Takeda's U.S. operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval, the company said in a statement Wednesday. The appointment comes as Takeda sees a competitive growth outlook with new product launches from the second half of 2026, Weber said in a statement. "Now is the right time,' he said, referring to the leadership change. Kim, a U.S. citizen, joined Takeda six years ago. Prior to running the U.S. operations, she was the company's head of plasma-derived therapies. Weber became the drugmaker's first non-Japanese CEO when he was promoted to the position in 2015. He expanded Takeda's global network and transformed the drugmaker into a biotechnology powerhouse specializing in gastroenterlogy, cancer, neurology, vaccines and rare diseases. Under Weber's leadership, Takeda bought U.K. drugmaker Shire PLC for $62 billion in 2019. Takeda's operating income jumped 86% to ¥417.5 billion ($2.7 billion) for the nine months ending in December, driven by stronger demand for its products, the sale of a business unit and the weak yen, the company said in a separate statement Wednesday. Revenue rose 9.8% to ¥3.6 trillion.
Wall Street Journal
30-01-2025
- Business
- Wall Street Journal
Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO
Takeda Pharmaceutical 4502 0.65%increase; green up pointing triangle raised its annual earnings forecasts despite posting lower quarterly net profit, and it said Julie Kim, who heads its U.S. business unit, will become chief executive in 2026. The Japanese drugmaker said Thursday that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.
Reuters
30-01-2025
- Business
- Reuters
Japan's Takeda says CEO Weber to step down, raises profit forecast
TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after 12 years in management at Japan's biggest drugmaker. Julie Kim, president of the company's U.S. unit, was named to succeed Weber in June. Weber spearheaded Takeda's $59 billion takeover of Shire Plc in 2019, which expanded the company's drug pipeline and global reach. The announcement came as Takeda raised its full-year profit after quarterly results that trailed analyst estimates. The company now expects operating profit to reach 344 billion yen from earlier guidance of 265 billion yen, citing strong product performance, operating efficiencies, and revised currency assumptions. Operating profit in the three months through end-December stood at 66.9 billion yen ($432.56 million), the company said, versus 104.9 billion yen a year earlier and a consensus profit estimate of 78.1 billion yen in an LSEG survey of six analysts. The company said in May it would re-organise to improve profitability and refocus on drug research and development. Takeda has cut jobs or transferred staff at centres in the United States and in October announced an early retirement plan for some employees in Japan. The company is trying to rebuild its drug pipeline after losing patent protection on major earners and to recover from clinical trial failures of treatments for lung cancer and Crohn's disease that caused hefty impairment losses. It has high hopes for its experimental narcolepsy treatment TAK-861 and a psoriasis drug candidate bought from U.S.-based Nimbus Therapeutics in late 2022 for as much as $6 billion. Takeda gets more than half its revenue from the United States, which stands to be impacted by new import tariffs on pharmaceuticals pledged by U.S. President Donald Trump. The company on Tuesday declined to comment on the ratio of its drug production in the U.S. or the potential effect of such tariffs. Takeda's shares have slid nearly 5% in the past 12 months, underperforming a 9.9% advance in the benchmark Nikkei (.N225), opens new tab. ($1 = 154.6600 yen)
